Individualizing Treatment for Asthma in Primary Care (Full Study)

While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.

NCT Number	NCT07052942
Lead Sponsor	DARTNet Institute Collaborators: Penn State University, Icahn School of Medicine at Mount Sinai, University of Colorado, Denver, RAND, University of Washington, University of North Carolina, Reliant Medical Group, Kelsey Research Foundation, University of Kansas, University of Missouri-Columbia, John Peter Smith Health Network, Rutgers University, AdventHealth, Wake Forest University Health Sciences
Conditions	Asthma, Asthma Attack, Asthma Exacerbations
Enrollment	3,200 participants
Start Date	2025-08-01
Primary Completion	2029-11-15 (estimated)
Study Completion	2029-11-15 (estimated)
Updated on ClinicalTrials.gov	2025-10-29